Degarelix

Degarelix has been studied in 2 papers since 2020: none in people yet, 2 in animals; 1 in the past year. The research so far is in animals. The newest paper, Oct 27, 2026: “GnRH antagonist-induced ovarian suppression does not protect the ovarian reserve from cyclophosphamide chemotherapy in tumour-bearing mice”.

Intervention

2 papers study it1 more mentions it5 findingsUpdated Oct 27, 2026

PubChem ChEBI

1 new paper in 30 daysSee all 3 papers on degarelix

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country; 2 trials, none about aging.

None of its findings points the other way.

1 lab in 1 country
2 trials, none about aging

Funders: National Health and Medical Research Council and 2 more

Animals2

What did studies of degarelix find?

Studies of degarelix measured 4 outcomes; the most studied are ovarian reserve (1 study), ovulatory activity (1) and thymocyte and mature TEC subset recovery (1).

Ovarian reserve

no changein mice1

1 study

Degarelix showed no clear effect on ovarian reserve in mice (tumor-bearing mice receiving one or two doses of cyclophosphamide).
“failed to protect the ovarian reserve following either single or two doses of cyclophosphamide in both age groups.”
Animalstumor-bearing mice receiving one or two doses of cyclophosphamideovary
GnRH antagonist-induced ovarian suppression does not protect the ovarian reserve from cyclophosphamide chemotherapy in tumour-bearing mice
Frontiers in endocrinologyOct 27, 2026

Ovulatory activity

downin mice1

1 study

Degarelix decreases ovulatory activity in mice (orthotopic tumor-bearing mouse model).
“Degarelix suppressed ovulatory activity, as indicated by reduced corpora lutea number and ovarian volume.”
Animalsorthotopic tumor-bearing mouse modelovary
GnRH antagonist-induced ovarian suppression does not protect the ovarian reserve from cyclophosphamide chemotherapy in tumour-bearing mice
Frontiers in endocrinologyOct 27, 2026

Thymocyte and mature TEC subset recovery

upin mice1

1 study

Degarelix increases thymocyte and mature TEC subset recovery in mice after cyclophosphamide treatment; faster recovery kinetics in females.
“following cyclophosphamide treatment, degarelix enhanced thymocyte and mature TEC subset recovery, with faster recovery kinetics observed in females”
Animalsafter cyclophosphamide treatment; faster recovery kinetics in femalesthymus
Gender Disparity Impacts on Thymus Aging and LHRH Receptor Antagonist-Induced Thymic Reconstitution Following Chemotherapeutic Damage
Frontiers in immunologyMar 3, 2020

Thymic epithelial cell subsets

upin mice1

1 study

Degarelix increases thymic epithelial cell subsets in mice (middle-aged mice; effect less pronounced in females than in males).
“The regenerative effects of LHRH receptor antagonist, degarelix, on TEC subsets was also less pronounced in middle-aged females compared to males”
Animalsmiddle-aged mice; effect less pronounced in females than in malesthymus
Gender Disparity Impacts on Thymus Aging and LHRH Receptor Antagonist-Induced Thymic Reconstitution Following Chemotherapeutic Damage
Frontiers in immunologyMar 3, 2020

What is degarelix linked with?

Studies link degarelix with 1 measure, most often ovarian fibrosis (1 study).

Ovarian fibrosis

upin mice1

1 study

Degarelix is associated with ovarian fibrosis in mice (tumor-bearing mice treated with single-dose cyclophosphamide).
“degarelix was associated with increased ovarian fibrosis in young mice treated with single-dose cyclophosphamide”
Animalstumor-bearing mice treated with single-dose cyclophosphamideovary
GnRH antagonist-induced ovarian suppression does not protect the ovarian reserve from cyclophosphamide chemotherapy in tumour-bearing mice
Frontiers in endocrinologyOct 27, 2026